540222 Stock Overview
Manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 1/6 |
Laurus Labs Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹489.95 |
| 52 Week High | ₹517.90 |
| 52 Week Low | ₹358.70 |
| Beta | 1.12 |
| 11 Month Change | 3.35% |
| 3 Month Change | 13.70% |
| 1 Year Change | 31.46% |
| 33 Year Change | -0.32% |
| 5 Year Change | 617.67% |
| Change since IPO | 409.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| 540222 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 0.2% | -1.7% | 0.1% |
| 1Y | 31.5% | 48.6% | 33.4% |
Return vs Industry: 540222 underperformed the Indian Pharmaceuticals industry which returned 48.6% over the past year.
Return vs Market: 540222 underperformed the Indian Market which returned 33.4% over the past year.
Price Volatility
| 540222 volatility | |
|---|---|
| 540222 Average Weekly Movement | 4.3% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 3.9% |
Stable Share Price: 540222 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 540222's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 6,007 | Satyanarayana Chava | www.lauruslabs.com |
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs.
Laurus Labs Limited Fundamentals Summary
| 540222 fundamental statistics | |
|---|---|
| Market cap | ₹263.95b |
| Earnings (TTM) | ₹1.31b |
| Revenue (TTM) | ₹50.53b |
201.3x
P/E Ratio5.2x
P/S RatioIs 540222 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 540222 income statement (TTM) | |
|---|---|
| Revenue | ₹50.53b |
| Cost of Revenue | ₹24.60b |
| Gross Profit | ₹25.93b |
| Other Expenses | ₹24.62b |
| Earnings | ₹1.31b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.43 |
| Gross Margin | 51.32% |
| Net Profit Margin | 2.59% |
| Debt/Equity Ratio | 65.7% |
How did 540222 perform over the long term?
See historical performance and comparisonDividends
0.2%
Current Dividend Yield33%
Payout RatioDoes 540222 pay a reliable dividends?
See 540222 dividend history and benchmarks| Laurus Labs dividend dates | |
|---|---|
| Ex Dividend Date | Nov 06 2024 |
| Dividend Pay Date | Nov 23 2024 |
| Days until Ex dividend | 7 days |
| Days until Dividend pay date | 10 days |
Does 540222 pay a reliable dividends?
See 540222 dividend history and benchmarks